Compare AVEX & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVEX | JANX |
|---|---|---|
| Founded | N/A | 2017 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 866.3M | 840.4M |
| IPO Year | 2026 | 2021 |
| Metric | AVEX | JANX |
|---|---|---|
| Price | $16.45 | $16.40 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $47.00 |
| AVG Volume (30 Days) | ★ 2.5M | 1.5M |
| Earning Date | N/A | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.07 | $12.12 |
| 52 Week High | $22.45 | $35.34 |
| Indicator | AVEX | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 66.25 |
| Support Level | $15.07 | $13.00 |
| Resistance Level | $22.45 | $16.60 |
| Average True Range (ATR) | 1.82 | 0.72 |
| MACD | -0.18 | 0.22 |
| Stochastic Oscillator | 17.91 | 82.88 |
AEVEX Corp is a defense technology company delivering next-generation navigation and autonomy, uncrewed systems, and adaptable mission solutions engineered to need, delivered at speed, and built for the modern battlespace. Its solutions are sold to agencies and organizations within the DoW, SOF, IC, and allied international partners. The group offers products and solutions such as CompassCore, CompassVision, CompassEngage, Precision Strike Systems, Unmanned Surface Vessels, Long Endurance Aircraft, Additive Manufacturing, Full Spectrum Airborne ISR, Aircraft Modification and Testing, and Others.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.